Sol-Gel将向PellePharm支付470万美元的预付款,以及高达600万美元的开发和NDA验收里程碑,以及高达6400万美元的商业里程碑和分成。
Patidegib被Sol-Gel指定为SGT-610,用于治疗Go...查看全文
$Sol-gel(SLGL)$ 20-F Annual and transition report of foreign private issuers [Sections 13 or 15(d)] Accession Number: 0001178913-22-001373 Act: 34 Size: 9 MB 网页链接
$Sol-gel(SLGL)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001178913-22-001283 Act: 34 Size: 142 KB 网页链接
$Sol-gel(SLGL)$ SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals Accession Number: 0001178913-22-000389 Act: 34 Size: 103 KB 网页链接
$Sol-gel(SLGL)$ SC 13G Statement of acquisition of beneficial ownership by individuals Accession Number: 0001178913-22-000319 Act: 34 Size: 56 KB 网页链接
$Sol-gel(SLGL)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001178913-22-000028 Act: 34 Size: 2 MB 网页链接
$Sol-gel(SLGL)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001178913-21-003897 Act: 34 Size: 24 KB 网页链接
$Sol-gel(SLGL)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001178913-21-003615 Act: 34 Size: 3 MB 网页链接
$Sol-gel(SLGL)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001178913-21-003477 Act: 34 Size: 156 KB 网页链接
$Sol-gel(SLGL)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001178913-21-003426 Act: 34 Size: 138 KB 网页链接
$Sol-gel(SLGL)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001178913-21-002958 Act: 34 Size: 4 MB 网页链接